Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 1872Neoplasms 1257Colorectal Neoplasms 1059Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 803Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 450Ovarian Neoplasms 406Neoplasm Metastasis 405Colonic Neoplasms 405Uterine Cervical Neoplasms 400Recurrence 383Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 340Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

liposomal doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Ovarian Neoplasm Epithelial × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡